Eli Lil­ly buys it­self an an­ti­body R&D plat­form from Till­man Gern­gross’s Adimab

Eli Lil­ly has just ex­e­cut­ed on a turnkey an­ti­body plat­form deal with Till­man Gern­gross’s Adimab.
We don’t know the deal terms, but Lil­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.